Navigation Links
Orthomimetics Secures CE Mark Approval for Chondromimetic

CAMBRIDGE, England, January 14 /PRNewswire/ -- This approval enables the company to market its line of bioresorbable implants for bone and/or soft tissue repair in the EU. Orthomimetics' family of products was developed during a groundbreaking collaboration between the University of Cambridge and the Massachusetts Institute of Technology.

Chondromimetic is a novel off-the-shelf implant that helps to support the repair of defects involving both articular cartilage and bone - defects that can result from sports injuries, surgical intervention and other trauma. Articular cartilage damage and subsequent degeneration of the underlying bone are known to be a major cause of arthritis in young individuals.

CE-mark approval enables the company to market Chondromimetic in Europe, and comes earlier than originally forecast at the time of the company's December 2006 Series A financing. Orthomimetics will immediately launch a comprehensive post-market clinical-trial program for Chondromimetic, and is currently negotiating distribution agreements for key European territories. The company will pursue additional approvals in other global territories throughout 2009.

Commenting on the CE Mark approval, Dr Andrew Lynn, CEO of Orthomimetics, said:

"Orthomimetics is extremely pleased to be able to make Chondromimetic available for surgeons and patients in Europe. This approval is the result of a tremendous amount of hard work on the part of our surgeon advisors, scientific collaborators, and - most of all - our professional, dedicated team. We look forward to making Chondromimetic a clinical and commercial success."

Editors Notes:

Orthomimetics Limited is a medical technology company that specialises in the design, development, and manufacture of regenerative medical implants and minimally invasive delivery systems for the treatment of sports injuries, trauma and other conditions that affect knees, ankles and other articular joints. Formed in 2005 as the first spin-out venture from the Cambridge-MIT Institute, the company is bringing to market a line of medical device products designed to improve the treatment outcome of first-line surgical procedures for the regenerative repair of articular cartilage, meniscus, ligament and tendon injuries using natural biomaterials. These products are engineered to be compatible with existing surgical techniques and to work in combination with emerging cell- and biologics-based products.

For further information on Orthomimetics please go to our website: or contact Katherine Webster:

SOURCE Orthomimetics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Precision Therapeutics Secures $43 Million in Venture Capital Funding
2. DFine Secures $30 Million in Series D Funding
3. Ocean Nutrition Canada Limited Secures Their Position as the Largest Omega-3 EPA/DHA Ingredient Supplier in the World
4. Cohera Medical Secures $16.1 Million in Series B Financing
5. Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel
6. Almost Family Secures $75 Million Revolving Credit Facility
7. 1,000th Uninsured Virginia Patient Secures Access to Quality Medical Care Through Virginia Cares Uninsured Program (VCUP)
8. Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production
9. Global Med Technologies(R), Inc. Secures $6 Million Credit Facility From Silicon Valley Bank for Inlog Acquisition
10. PSS Systems Secures $18 Million in Financing
11. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
Post Your Comments:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: